Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 123,901 |
|
|||||
| News | - | ||||||
| Day High | 2.07 | Low High |
|||||
| Day Low | 1.865 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ProQR Therapeutics NV | PRQR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.09 | 4.84% | 1.95 | 14:51:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.90 | 1.865 | 2.07 | 1.86 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 948 | 123,901 | $ 1.97 | $ 243,527 | - | 1.11 - 3.29 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:51:04 | 18 | $ 1.955 | USD |
ProQR Therapeutics NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 162.71M | 81.35M | - | 6.59M | -28.12M | -0.35 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ProQR Therapeutics NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PRQR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.23 | 2.31 | 1.81 | 2.00 | 210,431 | -0.28 | -12.56% |
| 1 Month | 2.37 | 2.49 | 1.81 | 2.17 | 160,086 | -0.42 | -17.72% |
| 3 Months | 2.06 | 2.70 | 1.81 | 2.14 | 212,975 | -0.11 | -5.34% |
| 6 Months | 1.30 | 3.29 | 1.11 | 2.04 | 260,205 | 0.65 | 50.00% |
| 1 Year | 2.15 | 3.29 | 1.11 | 1.89 | 270,343 | -0.20 | -9.30% |
| 3 Years | 5.95 | 9.09 | 0.53 | 2.85 | 814,702 | -4.00 | -67.23% |
| 5 Years | 11.24 | 13.28 | 0.53 | 4.53 | 745,788 | -9.29 | -82.65% |
ProQR Therapeutics NV Description
| ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. |
